CasNo.2133-34-8,(S)-(-)-2-Azetidinecarboxylic acid,(2133-34-8) Suppliers

10 Metric Ton	Negotiable

Min.Order :10 Metric Ton
Purity: ≥98%
Payment Terms : L/C,D/A,D/P,T/T,MoneyGram

Keywords

(S)-2-AZETIDINE CARBOXYLIC ACID (2S)-azetidine-2-carboxylic acid :L-Azetidine-2-carboxylic acid, 98%

Quick Details

Appearance:White to nearly white powder
Application:medical intermediate
PackAge:inside:double PE bag outside:paper drum
ProductionCapacity:more than 10|Metric Ton|Day
Storage:awway from light, room temperature
Transportation:CIF by air or DAP by courier, FOB,EX works etc.

Superiority:

We have produced this product many years and now got scale production .Purity can reach more than 98%.

The Corporation's main product are high purity single molecular PEG series derivatives, hydroxyproline series derivatives, polypeptide long acting drug side chain and its intermediates (including Semaglutide side chain, liraglutide side chain, Degu insulin side chain, long-acting production hormone, etc.), and short peptide drugs modified side chains (semaglutide dipeptide, tetrapeptide).

Our company is working with innovative pharmaceutical companies to build a platform for research and development of polypeptide long-acting drugs, and is committed to building a systematic and diverse long-acting side chain library, establishing molecular blocks of polypeptide long-acting side chains, and providing various development solutions for customers to develop polypeptide long-acting drugs.

Details:

For set production, sales, research and development as one of the manufacturers. At present, the company has 2400 square meters of RESEARCH and development center, 1000 square meters of production workshop. Plan to build 12000 square meters of production base, according to GMP standard quality system management. In recent years, Pukang pharmaceutical has been approved by well-known pharmaceutical enterprises at home and abroad for more than ten times. The main products of the company are high purity single molecule polyethylene glycol derivatives, long-term drug side chains of polypeptides and their intermediates (including cimerlutide side chains, Liraglutide side chains, insulin Degludec side chains, human growth hormone side chains, etc.), short peptide drug modified side chains (dipeptide, tetrapeptide). The company is cooperating with innovation Pharmaceutical company to establish a long-term peptide drug development platform, committed to building a systematic variety of long-term peptide side chain library, establish long-term peptide side chain molecular blocks, and provide customers with a variety of long-term peptide drug development solutions. Companies adhering to the "quality first, technology first" concept, to provide customers around the world with the best products and the best service.